Literature DB >> 12670835

Basal and dynamic proinsulin-insulin relationship to assess beta-cell function during OGTT in metabolic disorders.

Andrea Tura1, Giovanni Pacini, Alexandra Kautzky-Willer, Bernhard Ludvik, Rudolf Prager, Karl Thomaseth.   

Abstract

The fasting proinsulin-to-insulin ratio is a currently used marker of beta-cell dysfunction. This ratio is calculated at the basal condition, but its behavior in dynamic conditions, i.e., during glucose stimulation, could be more informative. Given the different kinetics of the peptides, a mathematical model was necessary to analyze the oral glucose tolerance test (OGTT) data of insulin, C-peptide, and proinsulin in 55 healthy (NGT), 30 impaired glucose-tolerant (IGT), and 31 type 2 diabetic (T2DM) subjects. The model provided for secretion and disappearance of the peptides and an index of beta-cell function under dynamic conditions. Total proinsulin secretion during the OGTT was not different (P > 0.053) among NGT (0.17 +/- 0.01 mmol/l in 3 h), IGT (0.22 +/- 0.02), and T2DM (0.21 +/- 0.02) subjects. The proinsulin-to-insulin molar ratio measured from basal samples was higher (P < 0.0001) in T2DM (0.39 +/- 0.05) than in NGT (0.14 +/- 0.01) and IGT (0.13 +/- 0.02) subjects, and similar results (P < 0.003) were found by the dynamic index (0.27 +/- 0.04, 0.14 +/- 0.01, 0.15 +/- 0.01 in T2DM, NGT, IGT subjects, respectively). The basal ratio significantly correlated with the dynamic index, and the regression line slope was lower than 1 (0.43 +/- 0.08, 0.61 +/- 0.10, and 0.56 +/- 0.03 in NGT, IGT, and T2DM subjects, respectively, P < 0.0001). Impaired beta-cell function in T2DM could then be indicated by proinsulin-to-insulin indexes at both basal and dynamic phases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12670835     DOI: 10.1152/ajpendo.00104.2002

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  9 in total

1.  Proinsulin-to-C-peptide ratio versus proinsulin-to-insulin ratio in the prediction of incident diabetes: the Insulin Resistance Atherosclerosis Study (IRAS).

Authors:  R C Loopstra-Masters; S M Haffner; C Lorenzo; L E Wagenknecht; A J Hanley
Journal:  Diabetologia       Date:  2011-09-30       Impact factor: 10.122

2.  Activation of Insulin-PI3K/Akt-p70S6K Pathway in Hepatic Stellate Cells Contributes to Fibrosis in Nonalcoholic Steatohepatitis.

Authors:  Cindy X Cai; Hema Buddha; Shobha Castelino-Prabhu; Zhiwei Zhang; Robert S Britton; Bruce R Bacon; Brent A Neuschwander-Tetri
Journal:  Dig Dis Sci       Date:  2017-02-13       Impact factor: 3.199

3.  Evidence for association between polycystic ovary syndrome (PCOS) and TCF7L2 and glucose intolerance in women with PCOS and TCF7L2.

Authors:  Assel Biyasheva; Richard S Legro; Andrea Dunaif; Margrit Urbanek
Journal:  J Clin Endocrinol Metab       Date:  2009-04-07       Impact factor: 5.958

4.  Curcumin extract for prevention of type 2 diabetes.

Authors:  Somlak Chuengsamarn; Suthee Rattanamongkolgul; Rataya Luechapudiporn; Chada Phisalaphong; Siwanon Jirawatnotai
Journal:  Diabetes Care       Date:  2012-07-06       Impact factor: 19.112

5.  Congenital hyperinsulinism and glucose hypersensitivity in homozygous and heterozygous carriers of Kir6.2 (KCNJ11) mutation V290M mutation: K(ATP) channel inactivation mechanism and clinical management.

Authors:  Karen J Loechner; Alejandro Akrouh; Harley T Kurata; Carlo Dionisi-Vici; Arianna Maiorana; Milena Pizzoferro; Vittoria Rufini; Jean de Ville de Goyet; Carlo Colombo; Fabrizio Barbetti; Joseph C Koster; Colin G Nichols
Journal:  Diabetes       Date:  2010-10-27       Impact factor: 9.461

Review 6.  Insulin administration: present strategies and future directions for a noninvasive (possibly more physiological) delivery.

Authors:  Elena Matteucci; Ottavio Giampietro; Vera Covolan; Daniela Giustarini; Paolo Fanti; Ranieri Rossi
Journal:  Drug Des Devel Ther       Date:  2015-06-17       Impact factor: 4.162

7.  Impact of three oral antidiabetic drugs on markers of β-cell function in patients with type 2 diabetes: a meta-analysis.

Authors:  Jin Lu; Jiajie Zang; Huihua Li
Journal:  PLoS One       Date:  2013-10-25       Impact factor: 3.240

8.  Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency.

Authors:  Juan Camilo Arjona Ferreira; Michel Marre; Nir Barzilai; Hua Guo; Gregory T Golm; Christine McCrary Sisk; Keith D Kaufman; Barry J Goldstein
Journal:  Diabetes Care       Date:  2012-12-17       Impact factor: 19.112

9.  Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study.

Authors:  Michael A Nauck; Robert E Ratner; Christoph Kapitza; Rachele Berria; Mark Boldrin; Raffaella Balena
Journal:  Diabetes Care       Date:  2009-04-14       Impact factor: 17.152

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.